Drug Combo Proves Powerful Against Lung Cancer Plainview NY

A two-drug combination treatment in Plainview proved successful in safely slowing advanced non-small cell lung cancer in a recent clinical trial. In the study, a phase 3 trial involving 768 people with the disease, those who had erlotinib (Tarceva) added to their dose of the bevacizumab (Avastin) saw the progression of the disease slow more than if on bevacizumab alone.

Local Companies

Farida P Chaudhri MD
(718) 358-3057
146-01 45th Ave
Flushing, NY
JEFFREY LIPTON, MD
(718) 470-3460
269-01 76Th Avenue
New Hyde Park, NY
Craig Edward Devoe, MD
516-562-8973
300 Community Dr 9 Monti
Manhasset, NY
Willi Kreis, MD
300 Community Dr
Manhasset, NY
Lihong We, MD
718-460-2300
5916 174th St
Fresh Meadows, NY
Louis Juden Reed
(718) 863-8465
1180 Morris Park Ave
Bronx, NY
BEVERLY DRUCKER, MD
(203) 863-3737
77 Lafayette Place
Greenwich, CT
JOHN FIORE, MD
(646) 227-3813
650 Commack Road
Commack, NY
Carl David Atkins, MD
516-536-1455
242 Merrick Rd Ste 301
Rockville Centre, NY
Romeo D Balagot, MD
516-731-0124
4277 Hempstead Tpke Ste 107
Bethpage, NY
Data Provided by:
    

Provided By:

SATURDAY, May 30 (HealthDay News) -- A two-drug combination treatment proved successful in safely slowing advanced non-small cell lung cancer in a recent clinical trial.

In the study, a phase 3 trial involving 768 people with the disease, those who had erlotinib (Tarceva) added to their dose of the bevacizumab (Avastin) saw the progression of the disease slow more than if on bevacizumab alone. People on the combo therapy tolerated the drugs well and survived an average of 4.8 months before the disease grew worse, compared with 3.7 months for those on bevacizumab alone.

Non-small cell lung cancer, often linked to past tobacco use, is the most common of all lung cancers, according to the National Cancer Institute.

"This is the first study to show the addition of erlotinib to maintenance therapy prolongs progression-free survival in patients with advanced non-small cell lung cancer," the study's co-author, Dr. Vincent Miller, a thoracic oncologist at Memorial Sloan-Kettering Cancer Center in New York City, said in a news release from the center. "Knowing which patients will get the greatest benefit from this combination, based on the identification of biomarkers, will be an important next step in this research."

Maintenance therapy aims to slow a disease from getting worse and better the chance of surviving while recovering from stronger chemotherapy treatments, which can weaken and sicken the person.

Miller was to present the findings Saturday at the annual meeting American Society of Clinical Oncology, in Orlando, Fla.

Bevacizumab and erlotinib have previously shown promise in treating non-small cell lung cancer by blocking tumor growth.

More information

The American Cancer Society has more about non-small cell lung cancer.

SOURCE: Memorial Sloan-Kettering Cancer Center, news release, May 30, 2009

Copyright © 2009 ScoutNews, LLC. All rights reserved.

Read Article at HealthDay.com